SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- NatureWell, Incorporated (the "Company") (BULLETIN BOARD: NAWL) announced today that it has been granted a patent by the United States Patent and Trademark Office on a proprietary method for treating aches and pains.
Commenting on the patent approval, Senior Vice President of Research and Development, Dr. Don Brucker had this to say: "We feel that the patent gives us broad protection on a group of products that the Company has been developing, including, among others, products for PMS and arthritis. This is a significant event for the Company's ability to gain protection for products that we believe will be effective and can appeal to large markets."
James R. Arabia, Chief Executive Officer, added, "We are very pleased to have received approval for this new patent. In addition to inventing MigraSpray for the treatment of migraine headaches, Dr. Brucker has developed and continues to develop products that we feel will be covered by this new patent and which are important for the Company's future growth prospects."
The Company currently markets its migraine relief product under the name MigraSpray, http://www.migraspray.com/, which is a patented spray formulation, delivered sublingually, containing the herb feverfew, intended to provide fast relief and prevention from pain and other symptoms associated with migraine headaches. NatureWell is an emerging company engaged in the development, marketing and licensing of unique, proprietary healthcare products.
Statements made in this news release should be considered forward-looking and subject to various risks and uncertainties. Such forward-looking statements are based on management's beliefs and assumptions regarding information currently available, and are made pursuant to the "safe harbor" provisions of the federal securities laws. The Company's actual performance and results could differ materially from those expressed in the forward-looking statements due to certain risks and uncertainties that could materially impact the Company in an adverse fashion and are only predictions of future results, and there can be no assurance that the Company's actual results will not materially differ from those anticipated in these forward-looking statements. Such risks and uncertainties, include, but are not limited to, the Company's ability to secure adequate financing, the Company's ability to ship its products in a timely fashion, volume and timing of orders received, interruption of the manufacturing or distribution of the Company's products or of the supplies or ingredients used to manufacture the Company's products, the effectiveness of the Company's products and consumer perception as to the effectiveness of the products, competitive pricing pressures and the Company's ability to anticipate changes in the market. The Company has no obligation to publicly update or revise any of the forward-looking statements that may be in this news release.
NatureWell, Incorporated
Commenting on the patent approval, Senior Vice President of Research and Development, Dr. Don Brucker had this to say: "We feel that the patent gives us broad protection on a group of products that the Company has been developing, including, among others, products for PMS and arthritis. This is a significant event for the Company's ability to gain protection for products that we believe will be effective and can appeal to large markets."
James R. Arabia, Chief Executive Officer, added, "We are very pleased to have received approval for this new patent. In addition to inventing MigraSpray for the treatment of migraine headaches, Dr. Brucker has developed and continues to develop products that we feel will be covered by this new patent and which are important for the Company's future growth prospects."
The Company currently markets its migraine relief product under the name MigraSpray, http://www.migraspray.com/, which is a patented spray formulation, delivered sublingually, containing the herb feverfew, intended to provide fast relief and prevention from pain and other symptoms associated with migraine headaches. NatureWell is an emerging company engaged in the development, marketing and licensing of unique, proprietary healthcare products.
Statements made in this news release should be considered forward-looking and subject to various risks and uncertainties. Such forward-looking statements are based on management's beliefs and assumptions regarding information currently available, and are made pursuant to the "safe harbor" provisions of the federal securities laws. The Company's actual performance and results could differ materially from those expressed in the forward-looking statements due to certain risks and uncertainties that could materially impact the Company in an adverse fashion and are only predictions of future results, and there can be no assurance that the Company's actual results will not materially differ from those anticipated in these forward-looking statements. Such risks and uncertainties, include, but are not limited to, the Company's ability to secure adequate financing, the Company's ability to ship its products in a timely fashion, volume and timing of orders received, interruption of the manufacturing or distribution of the Company's products or of the supplies or ingredients used to manufacture the Company's products, the effectiveness of the Company's products and consumer perception as to the effectiveness of the products, competitive pricing pressures and the Company's ability to anticipate changes in the market. The Company has no obligation to publicly update or revise any of the forward-looking statements that may be in this news release.
NatureWell, Incorporated
© 2004 PR Newswire
